secwatch.observer — SEC 8-K summary
======================================

Issuer:     CHAMPIONS ONCOLOGY, INC. (CSBR)
CIK:        0000771856
Form:       8-K
Filed at:   2024-12-11T23:59:59+00:00
Accession:  0001628280-24-050789
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Champions Oncology Q2 FY2025: Revenue $13.5M, Net Income $730K, Adj. EBITDA $1.1M
--------------------------------------------------------------------------------

- Q2 revenue rose 17% YoY to $13.5M; gross margin improved to 45% from 43%
- Net income of ~$730K vs. $2.0M operating loss a year ago
- Adjusted EBITDA of $1.1M, reversed from a $1.4M loss in Q2 FY2024
- Company guides FY2025 revenue growth of at least 10%-15%, citing core strength and new data platform revenue
- No debt; cash on hand ~$2.8M; data monetization highlighted as a transformative additional revenue stream

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/771856/000162828024050789/0001628280-24-050789-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/771856/000162828024050789/csbr-20241211.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-050789

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer